Showing results (1-10 of 34) with videos related to
Sort By:
Pageof 4
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 22, 2022
Economic burden in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitorsYanyu Wu, Kaili Ren, Yin Wan, et al.JTO Clinical and Research Reports|February 24, 2022
EGFR Testing Patterns and Detection of EGFR Exon 20 Insertions in the United StatesHuamao M Lin, Yu Yin, Victoria Crossland, et al.Future Oncology (London, England)|April 28, 2020
Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access programHuamao M Lin, Xiaoyun Pan, Peijie Hou, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 11, 2023
Establishing Meaningful Change Thresholds in Patient-Reported Outcomes Among Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in ALTA-1L TrialJennifer L Beaumont, Huamao M Lin, Erin Goodman, et al.Clinical Lung Cancer|November 30, 2020
Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung CancerMohammad Jahanzeb, Huamao M Lin, Xiaoyun Pan, et al.Journal of Medical Economics|April 30, 2020
Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitorsHuamao M Lin, Xiaoyun Pan, Peijie Hou, et al.The Oncologist|June 4, 2020
Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung CancerMohammad Jahanzeb, Huamao M Lin, Xiaoyun Pan, et al.Advances in Therapy|June 25, 2024
Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLCKonstantinos Arnaoutakis, Yin Wan, Jennifer Elliott, et al.Clinical Lung Cancer|November 14, 2022
Real-world ALK Testing Trends in Patients With Advanced Non-Small-Cell Lung Cancer in the United StatesHuamao M Lin, Yanyu Wu, Yu Yin, et al.Lung Cancer Management|December 15, 2020
Humanistic burden of living with anaplastic lymphoma kinase-positive non-small-cell lung cancer: findings from the ALKConnect patient insight network and research platformHuamao M Lin, Xiaoyun Pan, Alyssa Biller, et al.Pageof 4